Study of Tocilizumab to Treat Polymyalgia Rheumatica
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the
tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients
with polymyalgia rheumatica (PMR).